Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial Meeting Abstract


Authors: Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; Sahai, V.; Oh, D. Y.; Liao, C. Y.; Millward, M.; Perez, D. R.; Ferte, C.; Blakesley, R.; Wolf, B.; Subbiah, V.; Kelley, R. K.
Abstract Title: Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Meeting Title: ESMO Congress 2022
Journal Title: Annals of Oncology
Volume: 33
Issue: Suppl. 7
Meeting Dates: 2022 Sep 9-13
Meeting Location: Paris, France
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2022-09-01
Start Page: S1381
Language: English
ACCESSION: WOS:000866211602416
DOI: 10.1016/j.annonc.2022.08.006
PROVIDER: wos
Notes: Meeting Abstract: LBA12 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alison Michele Schram
    123 Schram